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Objective: The goal of the OSCAR programme is to evaluate the performances of genotypic HIV-1 tropism testing in
clinical practice using the enhanced sensitivity version of Trofile (ESTA) as reference-assay.
Methods:HIV-1 coreceptor-usage was assessed using plasma samples from 406 HIV-1 infected patients by ESTA and
by gp120 V3 population-sequencing followed by Geno2pheno (set at a False Positive Rate [FPR] of 10% and 5%).
Results: ESTA was successful in 365 (89.9%) samples indicating R5 in 254 (69.6%), and DM/X4 in 111 (30.4% of sam-
ples (104 [28.5%] DM and 7 [1.9%] X4). Genotypic-testing successfully assessed viral tropism for all 406 samples, in-
cluding the 41 with undetermined result by ESTA. Genotypic-tropism testing at a FPR of 5% and 10% was 81.1% and
78.4% concordant with ESTA, respectively. Despite a sensitivity of 48.7% and 55.9% at a FPR of 5% and 10%, re-
spectively, a high concordance (specificity: 95.3% for FPR of 5% and 88.2% for FPR of 10%) between genotypic-tro-
pism testing and ESTA was reached in the detection of R5-tropic viruses.
Conclusion: Our results are in line with other European studies, and support the routine use of genotypic tropism
testing in clinical-settings for monitoring of HIV-1 infected patients candidate to or failing CCR5-antagonists.
KEY WORDS: HIV, Tropism, V3 loop, Genotypic tropism testing, Trofile
SUMMARY
Received May 27, 2010 Accepted June 19, 2010
INTRODUCTION
Human immunodeficiency virus type 1 (HIV-1)
entry into host cells is a multistep process that
requires sequential interactions of the envelope
glycoprotein gp120 first with the CD4 receptor
and then with one of a family chemokine recep-
tors, mainly CCR5 or CXCR4. The V3 loop in
HIV-1 gp120 has been shown to be critical for co-
receptor binding (Jensen et al., 2003). HIV-1
strains can be phenotypically classified accord-
ing to virus ability to use the CCR5 (R5) and/or
CXCR4 (X4) co-receptor. Thus, pure R5-tropic
and pure X4-tropic virus can use only the CCR5
and CXCR4 co-receptors to enter the target cell,
respectively (Berger et al., 1998), while dual-trop-
ic virus can use both co-receptors. In a virus pop-
ulation, the use of both co-receptors can be due
either to the presence of dual-tropic clones or to
a mixture of pure R5-tropic and X4-tropic clones
or both. This is cumulatively defined as
dual/mixed phenotype. 
HIV-1 co-receptor usage is of central pathological
and clinical importance. Indeed, it has been
shown that R5-tropic viruses are generally re-
sponsible for the establishment of the initial in-
fection and predominate in the majority of new-
ly HIV-1 infected patients, while the use of the
CXCR4 co-receptor is generally seen in more ad-
vanced stages of disease, and has been associat-
ed with a more rapid CD4 decline and progres-
sion to AIDS (Regoes et al., 2005; Berger et al.,
1998). In addition, CCR5-antagonists are a new
class of anti-HIV-1 drugs that specifically inhibit
the entry of CCR5-tropic HIV-1 strains into the
target cells by allosteric inhibition of the CCR5
co-receptor, (Dorr et al., 1995; Regoes et al., 2005;
Princen et al., 2005). Maraviroc is the first ap-
proved CCR5 antagonist, that entered clinical
practice in 2007. The determination of HIV-1 tro-
pism is mandatory before the prescription of
CCR5 antagonists. In particular, the recent guide-
lines recommend to use a co-receptor tropism as-
say whenever the use of a CCR5 antagonist is be-
ing considered (DHHS guidelines). However, the
definition of methodologies for a correct deter-
mination of HIV-1 co-receptor usage in clinical
practice is challenging. So far, several phenotyp-
ic assays have been developed to determine HIV-
1 tropism in clinical samples. Among them, the
original Trofile assay (Monogram Biosciences),
with a 10% sensitivity threshold for detection of
minority X4 virus population, has been used to
screen patients for inclusion in clinical trials of
CCR5 antagonists (Whitcomb et al., 2007; Gulick
et al., 2007; Gulick et al., 2008; Fätkenheuer et al.,
2008; Saag et al., 2009; Soriano et al., 2009). In
2008, an enhanced sensitivity version of Trofile
(ESTA) has been set up with a lower limit of sen-
sitivity for detecting minority X4 virus of 0.3% in
viral clone mixtures (Reeves et al., 2009).
However, the sensitivity of ESTA with clinical
samples at different levels of viremia is still poor-
ly documented. 
Phenotypic assays are complex, provided as a re-
mote service by specialized companies and fur-
ther made unpractical by high cost and long turn-
around times. In addition, most of them cannot
determine HIV-1 tropism in clinical samples with
viremia below 1,000 copies/ml and thus cannot
be used in the context of virological failure with
low viremia.
For all these reasons, genotypic tropism assays
are increasingly being used. They are based on
the population-based sequencing of the patient-
derived HIV-1 gp120 V3 domain, which is the ma-
jor determinant for co-receptor binding. The ge-
netic information contained in the V3 sequence
is then used to infer HIV-1 tropism by using web-
based bioinformatic interpretation tools.
Genotypic tropism assays have the great potential
for a routinely assessment of HIV-1 tropism, since
they are more widely available, relatively inex-
pensive and more rapid to perform than pheno-
typic assays. In addition, they can be used either
on plasma (through the amplification of viral
RNA) or on peripheral blood mononuclear cells
(PBMCs) (through the amplification of proviral
DNA), thus representing a feasible option for tro-
pism determination in the context of undetectable
viremia, such as simplification and intensifica-
tion therapeutic strategies. 
Current data indicate that genotypic assays can
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be a valuable tool for assessing HIV-1 tropism to
the point that they are already and routinely used
in clinical practice in several European countries,
such as United Kingdom, Germany, and France
(http://www.viro.med.uni-erlangen.de/nrz/rec-
ommendation080324.pdf; http://www.bhiva.org/
ClinicalGuidelines.aspx). In Italy, studies ad-
dressing this point at a national level are still
missing. 
In this context, the OSCAR (Optimizing the
Susceptibility to CCR5 Antagonists Response)
study was aimed at designing a new protocol for
V3 sequencing and at defining the performances
of genotypic tropism testing in clinical settings
by using as ESTA as reference assay. To fulfill this
goal, a pan-Italian network of clinicians and vi-
rologists has been established throughout Italy
that has allowed the collection of one of the
largest cohort of patients with matched genotyp-
ic and phenotypic Tropism results.
METHODS
Study population
This study includes 406 plasma samples from
HIV-1 infected patients, with plasma HIV-1 RNA
>100 copies/ml and naïve to maraviroc, enrolled
at 20 clinical centers throughout Italy in the
framework of the OSCAR programme. For each
patient, HIV-1 tropism was assessed both phe-
notypically by ESTA and genotypically by V3 se-
quencing and tropism prediction. Plasma sam-
ples for genotypic and phenotypic determination
of HIV-1 tropism were collected at the same time-
point. Demographic information, viral load, CD4
counts and antiretroviral treatment exposure
were recorded at the time of the analysis.
Phenotypic characterization of HIV-1 co-receptor
usage
ESTA was used for the phenotypic determination
of HIV-1 co-receptor usage. Briefly, the patient’s
derived env gene was amplified from plasma HIV-
1 RNA and cloned into an expression vector, that
is then co-transfected together with an env-defi-
cient HIV genomic vector carrying a luciferase
reporter gene into human embryonic kidney cells
(HEK293). The resulting pseudo-typed HIV par-
ticles were harvested and inoculated onto CX-
CR4-expressing and CCR5-expressing U87 cells.
Samples that produced a signal (measured as rel-
ative light units in a luciferase assay) only on
CCR5-expressing cells were considered pure R5-
tropic, and those that produced a signal only on
CXCR4-expressing cells were considered pure X4-
tropic; those that produced a signal on both cell
types are considered dual or mixed tropic (D/M).
Signal ablation with specific co-receptor in-
hibitors is used to confirm the assigned tropism.
Sequencing of HIV-1 gp120 V3 domain
The OSCAR programme was specifically de-
signed to set up a new protocol for population-
based sequencing of the V3 loop. The protocol
has been designed and optimized as follows. HIV-
1 RNA was extracted on plasma samples by
means of a commercially available kit (QIAamp
RNA Viral Mini kit, Qiagen) according to the
manufacturer’s instructions. The V3-containing
region of the env gene was then reverse-tran-
scribed and amplified using the forward primer
V3S2 5’CAGCACAGTACAATGTACACA 3’ (nu-
cleotide [nt]: 630-650 of HIV-1 HXB2 gp120 env
gene) and the reverse primer V3AS5 5’CTTCTC-
CAATTGTCCCTCA 3’ (nt: 1292-1310) (Figure 1,
Table 1). The conditions for reverse transcription
and amplification were: one cycle at 50°C for 30
min, one cycle 94°C for 2 min, 40 cycles (94°C
30s, 52°C 30s, 72°C 40s), and a final step at 72°C
for 10 min, using the following reaction mix: 25
ul of RNA template, 8 ul of 5 mM Mg++, 3 ul of
Dnase Rnase free water, 0.75 ul of each primer at
a concentration of 10 uM, 1 ul of Rnase out (40
U/ul), 1.5 ul of RT/Taq, 1 ul of dNTPs at a con-
centration of 10 mM for a total of 40 ul.
When the RT-PCR product was not visible on
agarose gel, a semi-nested PCR was used with the
inner forward primer V3S6 5’CTGTTAAATG-
GCAGTCTAGC3’ (nt: 682-702) and the reverse
primer V3AS5 (Figure 1, Table 1). Amplification
conditions were: one cycle at 93°C for 12 min, 40
cycles (95°C 30s, 52°C 30s, 72°C 40s) and a final
step at 72°C for 10 min, using the following re-
action mix: 5 ul of buffer taq 10X, 4 ul of Mg++
at a concentration of 25 mM, 32.5 ul of Dnase
Rnase free water, 0.9 ul of each primer at a con-
centration of 10 uM, 1 ul of dNTPs at a concen-
tration of 10 mM, 0.7 ul of Taq (5 u/ul) for a to-
tal of 45 ul.
The PCR product was purified by Microcon PCR
purification kit (Millipore). Negative and positive
Use of genotypic tropism testing in clinical practice 197
control samples were included in each PCR run to
exclude false-positive and false-negative reactions.
PCR-products were then sequenced by using the
BigDye terminator v.3.1 cycle sequencing kit
(Applied-Biosystems), and an automated se-
quencer (ABI-3100). Four different overlapping
sequence-specific primers were used to ensure
the coverage of the V3-sequence by at least two
sequence segments (Figure 1). The sequencing
conditions were: one cycle 96°C 3 min, 25 cycles
(96°C 30s, 50°C 10s, 60°C 4 min) and the follow-
ing primers were used: V3S6 5’CTGTTAAATG-
GCAGTCTAGC 3’, V3S5 5’ GTTAAATGGCAGTC-
TAGCAG 3’, V3AS1 5’ GAAAAATTCCCCTCCA-
CAATT 3’ and V3AS3bis 5’ CAATTTCTGGGTCC-
CCTC 3’ (Figure 1, Table 1). 
For a subset of samples, some modifications of
the above-mentioned protocol were followed. In
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FIGURE 1 - Location on HIV-1 gp120 coding region of the primers used for the amplification and sequencing of the
V3 loop. Primers S2 and AS5 were used for the RT-PCR reaction. Heminested PCR was directed by primers S6 and
AS5. Primers used for sequencing reaction are S6, S5, AS1, and AS3bis.
TABLE 1 - Overview of the primer and cycling conditions for V3 PCR.
PCR Nested PCR
Sense primer 5’-CAGCACAGTACAATGTACACA-3’ 5’- CTGTTAAATGGCAGTCTAGC -3’
Antisense primer 5’-CTTCTCCAATTGTCCCTCA- 3’ 5’-CTTCTCCAATTGTCCCTCA-3’
PCR settings 30 mins 50°C, 1 cycle 12 mins
2 mins 94°C, 1 cycle 93°C, 1 cycle
30s 94°C 30s 95°C
30s 52°C, 40 cycles 30s 52°C 40 cycles
40s 72°C 40s 72°C
10 min 72°C 1 cycle 10 min 72°C 1 cycle
PCR, polymerase chain reaction.
} }
particular, thirthy five plasma samples was se-
quenced with an alternative method. Briefly RT-
PCR was carried out with a 40 µl volume con-
taining 10 µl sample RNA. 16 µl of MMix1, that
contain 0.7 µl forward primer V3S2 (5’
CAGCACAGTACAATGTACACA 3’) and reverse
primer V3AS5 (5’ CTTCTCCAATTGTCCCTCA 3‘)
[15 µM], 1.8 µl dNTPs [10 mM], 1.2 µl dithio-
threitol (DTT), 0.6 µl RNase Inhibitor [40 U/µl],
14.5 µl steril water, was mixed with the sample.
The Second MMix (11.7 µl RT-PCR buffer, 06 µl
Rnase-inhibitor, 1.2 µl RT Enzyme and 2.9 µl
Dna Polymerase) was added after 10 min at 50°C.
RT-PCR was run with the following temperature
program: 20 min at 50°C and 2 min at 94°C, fol-
lowed by 40 cycles with 30 s at 94°C, 30 s at 57°C,
and 120 s at 68°C and a final extension for 7 min
at 68°C. 
CLIP sequencing reaction was performed by us-
ing a 7-deaza-dGTP Cy5/Cy5.5 dye primer cycle
sequencing kit (Siemens Healthcare Diagnostics,
Milan Italy) according to the manufacturer’s in-
structions. The four CLIP reaction mixtures con-
tained 2.8 µl CLIP buffer, 8.8 µl molecular water,
2.8 µl forward primer V3S6 (5’-Cy5.5-CTGT-
TAAATGGCAGTCTAGC-3’) and reverse primer
V3AS3bis (5’-Cy5-5’CAATTTCTGCCCCTC GGT-
3’) [3 µM], 5l sample cDNA, 3 µl of the four ter-
minator nucleotides, and 4.4 µl Thermosequenasi
Enzyme [32U/µl]. The CLIP-specific cycling pro-
gram was 5 min at 94°C, followed by 30 cycles of
20 s at 94°C, 20 s at 55°C, and 60 s 70°C and fi-
nal extension for 7 min at 70°C. Thereafter, Stop
Loading Dye (6 µl) was added. Samples were
heated to 94°C for 3 min and incubated at 4°C.
Fragments were separated on a TruGene Tower
(Siemens Healthcare Diagnostics, Milan Italy)
with a 6% polyacrylamide gel. Sequence data
were acquired and analyzed using the OpenGene
DNA Sequencing System and read against a new-
ly created HIV-1 V3 loop sequence-specific refer-
ence library. 
Genotypic prediction of viral tropism
HIV-1 co-receptor usage was inferred from the
V3 nucleotide sequence by using the geno2pheno
algorithm available at the following website
http://coreceptor.bioinf.mpi-inf.mpg.de/. The sys-
tem is based on a support vector machine
methodology that has been trained with a set of
V3 nucleotide sequences with known phenotyp-
ic tropism. The tool can also analyze amino-acid
mixtures deduced from degenerate base calls. The
result of the interpretation is given as a quanti-
tative value, the false positive rate (FPR), that de-
fines the probability of classifying an R5 virus
falsely as X4. 
HIV-1 co-receptor usage was inferred by using
both the clonal and the clinical version of
geno2pheno set at FPR of 10% and 5%. For clin-
ical inference of viral tropism, viremia at the time
of V3 sequencing and nadir of CD4 cell count
were used.
Reproducibility of the test and validation 
of clinical center participating in the OSCAR
programme
The OSCAR programme was designed to set up
a new protocol for V3 sequencing to be shared
with the majority of clinical and virological cen-
ters in Italy. For this reason, a validation proce-
dure for each virological center has been set up.
In particular, for each center, 10 plasma samples
were processed in duplicate, one by the center to
be validated and the other by the reference cen-
ter. In particular, 4 reference centers have been
identified in Rome, Milan, Siena, and Padova;
these centers have been previously validated us-
ing the same above-mentioned procedure. The
validation process was considered successful if
the V3 nucleotide sequences obtained from the
same plasma sample showed a degree of simi-
larity of >95% and no change in HIV-1 tropism
determination was observed. The validation was
successful for all the 20 centers involved in the
OSCAR programme.
Statistical analysis
To assess the performances of genotypic tropism
testing, the sensitivity and specificity for the de-
tection of X4 variants and their 95% confidence
intervals (95% CIs) were calculated considering
ESTA as reference assay. Sensitivity values were
calculated as the proportion of samples that were
considered as harboring X4-tropic viruses by
genotypic test within the whole group of DM/X4
viruses detected by ESTA. Specificity values were
reported as the proportion of patients with R5
viruses by genotype within all the R5 viruses by
phenotypic test. Data were analyzed using the sta-
tistical software package SPSS (SPSS Inc.,
Chicago, IL).
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Phylogenetic analysis
For each sample, HIV-1 subtype was determined
by using the geno2pheno algorithm and con-
firmed by phylogenetic analysis of V3-containing
nucleotide sequences. In particular, all the se-
quences were aligned and compared with refer-
ence sequences for the Major HIV-1 subtypes,
available at: http://hiv-web.lanl.gov/content/hiv-
db/SUBTYPE_REF/align.html using CLUSTAL X
(Thompson et al., 1994). The sequences were then
manually edited by the Bioedit program (Hall et
al., 1999). Phylogenetic trees were generated us-
ing GTR Model of substitution with both NJ and
Maximum Likelihood (ML) tree building meth-
ods (Swafford KL, 1999). The best fitting nu-
cleotide substitution model was tested with the
Hierarchical Likelihood Ratio Test (HLRT) im-
plemented in the Model Test V3.0 software
(Posada et al., 1998). The statistical robustness
within each phylogenetic tree was confirmed with
a bootstrap analysis using 1000 replicates for the
Neighbor-Joining (NJ) tree. All calculations were
performed with PAUP* 4.0b10 (http://paup.csit.
fsu.edu/about.html) software. For 39 patients,
available pol sequences were used to confirm
HIV-1 subtype by phylogenetic analysis (Alteri et
al., 2008). Phylogenetic analysis was also used to
identify potential cross-contaminations during
the sequencing process.
RESULTS
Patient’s characteristics
This study included 406 patients with HIV-1 RNA
>100 copies/ml and naïve to maraviroc. Their
clinical and viro-immunological characteristics
are shown in Table 2. At the time of sample col-
lection, the median viremia was 4.3 (IQR: 3.5-4.9)
log10 HIV-1 RNA copies/ml, and the median CD4
count was 310 (IQR:193-464) cells/ul. The large
majority of patients harbored HIV-1 B subtype
(N = 335, 82.5%). Other non-B subtypes or re-
combinant forms observed at a frequency >2%
were: F (N = 22, 5.4%), CRF02_AG (N = 19, 4.7%),
C (N = 10, 2.5%). 
Therapy status was known for 334 (82.3%) pa-
tients. Among them, 255 (62.8%) were treatment-
experienced patients. The proportion of anti-
retroviral-treated patients was similar in B and
non-B subtypes (61.3% versus 67.1%). No statis-
tically significant differences in viremia and CD4
cell count were observed between drug-naïve and
treatment-experienced patients infected with
HIV-1 B subtype (4.6 [3.8-5.0] log10 copies/ml ver-
sus 4.2 [3.4-4.9] log10 copies/ml, and 325 [164-
523] log10 copies/ml versus 307 [193-450] log10
copies/ml, P>0.100).
Phenotypic characterization of HIV-1 co-receptor
usage
Among the 406 plasma samples collected for the
study, ESTA was obtained for 365 (89.9%) sam-
ples indicating R5 in 254 (69.6%), and DM/X4 in
111 (30.4% of samples (104 [28.5%] DM and 7
[1.9%] X4) (Table 2). A significant lower preva-
lence of pure R5-tropic viruses and a higher
prevalence of DM-tropic viruses was observed in
patients infected with HIV-1 B subtype than in
those infected with non-B subtypes or recombi-
nant forms (R5: 67.0% versus 82.3%, P=0.022;
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TABLE 2 - Patients’ characteristics.
Number of patients 406
Male sex, number (%) 229 (56.4)
HIV-1 subtype, number (%)
B  335 (82.5)
F 22 (5.4)
CRF02_AG 19 (4.7)
C 10 (2.5)
Other 20 (4.9)
HIV-1 RNA load (log copies/ml)
Median 4.3
Interquartile range 3.5-4.9
CD4 cell count (cells/ul)
Median 310
Interquartile range 193-464
Nadir CD4 cell count (cells/ul)
Median 186
Interquartile range 53-320
Therapy status, number (%)
Treatment-experienced 255 (62.8)
Drug-naive 79 (19.5)
Not available 72 (17.7)
Trofile high sensitivity, number (%)
R5 254 (62.6)
X4 7 (1.7)
dual/mixed 104 (25.6)
not available 41 (10.1)
DM: 30.7% versus 17.7%, P=0.045). All the 7 pure
X4-tropic viruses were found in patients infect-
ed with HIV-1 B subtype. 
In the set of HIV-1 B subtype infected patients,
we observed a higher prevalence of R5-tropic
viruses and a lower prevalence of DM/X4-tropic
viruses in drug-naïve than in treatment-experi-
enced patients, even if not statistically significant
(R5: 74.5% versus 62.6%, DM/X4: 25.5% versus
37.4%, P>0.100).
Evaluation of the performance of genotypic
tropism testing
Efficiency of V3 sequencing
The protocol for V3 sequencing set up in the
framework of the OSCAR programme showed an
overall efficiency of 84.2%. This efficiency varied
according to the level of viremia (Figure 2). In
particular, for viremia ranging between 100-500
copies/ml, the rate of successful sequencing was
63%, it progressively increased to 81% and 88%
for viremia ranging between 500-1,000 copies/ml
and 1,000-10,000 copies/ml, respectively, and
reached ~95% for viremia >10,000 copies/ml
(Figure 2). The efficiency of V3 sequencing was
not affected by HIV-1 subtype.
Accuracy of genotypic tropism testing in detecting
X4-tropic using ESTA as reference
We defined the accuracy of genotypic tropism
testing in detecting X4-tropic viruses separately in
the set of 303 matched genotypic and phenotyp-
ic results from patients infected with HIV-1 B
subtype and in the set of 62 matched genotypic
and phenotypic results from patients infected
with non-B subtypes or recombinant forms (Table
3). We used the geno2pheno algorithm (both the
clonal and the clinical version) as interpretation
tool since it is so far recognized as the most reli-
able and robust algorithm for tropism determi-
nation. The geno2pheno algorithm provides a
quantitative value, the FPR, that is a measure of
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FIGURE 2 - V3 sequencing efficiency stratified by viremia levels (HIV-1 RNA copies/ml). In order to provide a com-
prehensive determination of the efficiency of V3 sequencing, the rate of successful sequencing has been determined
in a set of 592 samples, including samples involved in the OSCAR programme, and also other plasma samples test-
ed so far for both clinical and research purposes.
HIV-1 prediction to use the CCR5-coreceptor. We
used as cut-off to discriminate between an R5-
using or X4-using virus a FPR of 10%, proposed
by the German Recommendations of the National
Reference Centre for Retrovirus for determining
HIV-1 co-receptor usage, and a FPR of 5%, re-
cently used to analyze V3 sequencing obtained
from patients enrolled in the Phase III Clinical
trial Motivate (Harrigan et al., 2009). If the FPR
provided by geno2pheno for a specific V3 se-
quence is higher than the established cut-off, the
prediction of HIV-1 co-receptor usage is R5. The
accuracy measures of the clonal and clinical ver-
sion of geno2pheno algorithm are now reported: 
1) Analysis of the clonal version of geno2pheno. By
analyzing the 303 matched genotypic and phe-
notypic results from patients infected with HIV-
1 B subtype, we found that the overall concor-
dance between ESTA and geno2pheno at a FPR
of 5% and 10% was 80.5% and 77.6%, respec-
tively (Table 3). The specificity (that measures the
concordance between ESTA and genotypic tro-
pism testing in detecting R5-viruses) was 96.0%
and 89.0% and sensitivity (that measures the con-
cordance in detecting DM/X4-viruses) was 49%
and 55% when the FPR was set at 5% and 10%,
respectively (Table 3). The performances of geno-
typic tropism testing in the set of 62 matched
genotypic and phenotypic results from patients
infected with HIV-1 non B subtypes were not sig-
nificantly different from those observed for B sub-
type (Table 3). 
2) Analysis of the clinical version of geno2pheno. In
a subset of 148 HIV-1 B subtype infected patients,
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TABLE 3 - Performances of genotypic tropism testing using the enhanced sensitivity version 
of Trofile as reference assay
Geno2pheno algorithm ESTA Concordance Sensitivity Specificity Accuracy
Clonal Version R5 D/M X4 Total % (95%CI) (95%CI) (95%CI)
B subtype
R5 195 50 1 246 80.5 0.49 0.96 0.72 
FPR 5% X4 8 43 6 57 (0.39-0.59) (0.93-0.99) (0.65-0.78)
Total 203 93 7 303
R5 180 44 1 225 77.6 0.55 0.89 0.72
FPR 10% X4 23 49 6 78 (0.45-0.65) (0.84-0.93) (66-79)
Total 203 93 7 303
Non-B subtypes
R5 47 6 0 53 83.9 0.45 0.92 0.69
FPR 5% X4 4 5 0 9 (0.16-0.75) (0.85-0.99) (0.49-0.88)
Total 51 11 0 62
FPR 10% R5 44 4 0 48 82.3 0.64 0.86 0.75
X4 7 7 0 14 (0.35-0.92) (0.76-0.96) (57-93)
Total 51 11 0 62
Geno2pheno algorithm ESTA Concordance Sensitivity Specificity Accuracy
Clinical Versiona R5 D/M X4 Total % (95%CI) (95%CI) (95%CI)
FPR 5% R5 93 30 1 124 75.7 0.34 0.92 0.74
X4 8 16 0 24 (0.20-0.48) (0.87-0.07) (0.67-0.81)
Total 101 46 1 148
FPR 10% R5 88 26 1 0 73.0 0.42 0.87 0.73
X4 13 20 0 23 (0.28-0.57) (0.81-0.94) (0.66-0.80)
Total 101 46 1 148
aThe performances of the clinical version of the geno2pheno algorithm have been evaluated in a subset of 148 HIV-1 B subtype infected patients. 
Abbreviation: ESTA, Enhanced Sensitivity Version of Trofile.
we also evaluated the concordance between the
clinical version of geno2pheno algorithm and ES-
TA (Table 3). Compared to the clonal version, the
clinical version of geno2pheno takes into account
the value of viremia at the time of V3 genotyping
and the value of nadir CD4 cell count. The clini-
cal version was 75.7% and 73.0% concordant with
ESTA when the FPR was set at 5% and 10%, re-
spectively, with a specificity ranging from 92% to
87% and a sensitivity ranging from 34% to 42%,
respectively. Thus, in our dataset, the perform-
ances of the clinical version were not significantly
higher than that observed for the clonal one. 
DISCUSSION
The OSCAR study has evaluated the perform-
ances of a genotypic tropism testing in clinical
settings using ESTA as reference assay in one of
the largest set of matched genotypic and pheno-
typic results collected so far. This has been feasi-
ble by the establishment of an extensive network
of clinicians and virologists throughout Italy that
has allowed the collection and analysis of 406
matched genotypic and phenotypic results. In line
with other European studies, this study supports
the reliability and the use of genotypic tool for
tropism determination in clinical practice. 
Several studies have evaluated the performances
of genotypic tropism testing using the original
version of Trofile or other phenotypic assays as
reference (Low et al., 2007; Poveda et al., 2007;
Raymond et al., 2008; Poveda et al., 2009; Chueca
et al., 2009; Harrigan et al., 2009; Seclen et al.,
2009). The performances of genotypic tropism
testing in comparison to ESTA have been as-
sessed only in a very limited number of studies
using a limited number of patients (Strang et al.,
2009, De Luca et al., 2009, Sanchez et al., 2009). 
Our and the above-mentioned studies are in
agreement regarding the high concordance be-
tween genotypic and phenotypic tropism testing
(including ESTA) in the detection of R5-tropic
viruses. For instance, the specificity observed in
our dataset ranges from 86% to 96% when the
clonal version of geno2pheno has been used.
Conversely, a lower concordance is generally ob-
served in the detection of DM/X4 viruses (sensi-
tivity in our cohort ranging from 42% to 64%).
This result can be explained either by the fact that
genotypic tropism testing cannot detect X4-trop-
ic viruses representing less than ~10-20% of vi-
ral population, or by the fact that the current al-
gorithms for HIV-1 tropism prediction do not
take into account additional regions in the env
gene, outside the V3 loop. Even if the clinical rel-
evance of including additional regions remains
to be established, previous studies have demon-
strated that mutations in the V1/V2 loops and the
C4 region of the gp120 are involved in mecha-
nisms underlying co-receptor binding and usage
(Suphaphiphat et al., 2010; Pastore et al., 2006).
A recent study has also reported an increase in
the accuracy of interpretation when both V2 and
V3 were used compared to V2 or V3 alone
(Thielen et al., 2007). 
Despite this lower sensitivity, recent studies have
clearly shown that genotypic tropism testing is
comparable with Trofile assay in predicting viro-
logical response to a maraviroc containing
HAART regimen. In particular, the virological re-
sponse to a maraviroc-containing regimen has
been retrospectively predicted using the original
version of Trofile and population-based V3 se-
quencing in a cohort of treatment-experienced
patients enrolled in the framework of two phase
III clinical trials MOTIVATE 1 and 2 and in the
1029 study (Harrigan et al., 2009). Both Trofile
and population-based V3 sequencing were equal-
ly successful in predicting virological response at
week 12 and 24. Indeed, the percentage of viro-
logical success (viremia <50 copies/ml) at week
24 was 46.4% and 46.1% when the baseline pres-
ence of R5-tropic viruses was determined by
Trofile or V3-sequencing, respectively (Harrigan
et al., 2009). Similar results have been recently
observed in drug-naive patients enrolled in the
MERIT trials using ESTA and V3-sequencing (Mc
Govern et al., 2010). Thus, these studies (although
not randomized) support the use of genotyping
in clinical settings to select candidates for mar-
aviroc treatment. In addition, the 1029 study has
shown that 45% of patients classified as R5 by
the original Trofile and then reclassified as D/M
by ESTA reached virological success (viremia <50
copies/ml) at week 48 of a maraviroc-containing
regimen. In particular, by using the ultra-deep se-
quencing methodology, a rapid decline of viremia
(3 log) has been observed at week 12 in patients
where X4-tropic viruses were present in less than
10% of the entire viral population (Swenson et
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al., 2009). Another recent study have highlighted
the ability of a maraviroc-containing regimen to
suppress HIV-1 replication in presence of DM-
tropic viruses (Garcia et al., 2009; Garcia et al.,
2010). Thus, overall results suggest that the use
CCR5 antagonists could be enlarged to select pa-
tients with DM-tropic viruses and underline the
need of studies aimed at defining a more precise
threshold of X4-tropic viruses below which a
CCR5 antagonist together with other active drugs
can be safely used in different clinical contexts. In
this light, the use of highly sensitive assay for the
determination of HIV-1 tropism (such as ESTA)
could limit the number of patients that can ben-
efit at least partially from treatment with a CCR5
antagonist. 
Genotypic tropism testing has been also shown
to be a valid and accurate assay in predicting the
risk of clinical progression in both drug-naïve and
treatment-experienced patients (Fouchier et al.,
1992; De Jong et al., 1992; Brumme et al., 2004;
Delobel et al., 1999; Lin et al., 2010). In particu-
lar, in a prospective cohort study of patients ini-
tiating antiretroviral regimen, patients with X4-
tropic viruses predicted by genotyping had earli-
er mortality after starting therapy despite achiev-
ing viral suppression to less than 500 copies/ml
compared with patients with R5-viruses. Again,
these results support the use of genotypic tropism
testing can be a valuable tool in clinical practice
not only to determine patients that can benefit
CCR5 antagonist treatment but also for an opti-
mized monitoring of HIV-1 infected patients.
The methodology of V3 sequencing that has been
designed in the framework of the OSCAR pro-
gramme is characterized by a high rate of effi-
ciency even in presence of viremia lower than
1,000 copies/ml. Indeed, the rate of successful se-
quencing was 63% and 81% for viremia ranging
from 100-500 copies/ml and 500-1,000 copies/ml,
respectively, and reached ~95% for viremia
>10,000 copies/ml. The availability of method-
ologies that can assess HIV-1 co-receptor usage
even when viremia is low, is crucial since they
can be used even in those antiretroviral-treated
patients with persistently low, but detectable, lev-
els of HIV-1 RNA in the range of 50-1000
copies/ml. 
In addition, the methodology of V3 sequencing
used in this study is based on a single round of
amplification of the V3 region. In other studies,
a triplicate round of amplification has been per-
formed (Harrigan et al., 2009; Mc Govern et al.,
2010). The use of single versus triplicate geno-
typic analysis is still matter of debate. Indeed,
preliminary data from clinical trials have sug-
gested that genotypic analysis in triplicate may
increase the detection of X4-tropic viruses.
However, a recent study has evaluated the effect
of triplicate testing on genotypic tropism predic-
tion in routine clinical practice and has found
that the triplicate testing resulted in an enhanced
detection of X4-variants only in a small percent-
age of patients (Wensing et al., 2010). Further
studies are necessary to evaluate the clinical sig-
nificance of triplicate versus single genotypic
analysis for tropism prediction. 
In conclusion, in line with other European stud-
ies, our study supports the routine use of geno-
typic tropism testing in clinical settings for mon-
itoring HIV-1 infected patients and for a better
tuning of in vivo efficacy of CCR5 antagonists.
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